Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	55.86	92.83	65.65	74.78	43.25
Short-Term Investments	435.05	334.98	411.52	582.57	392.91
Cash & Cash Equivalents	490.91	427.81	477.17	657.35	436.16
Cash Growth	14.75%	-10.34%	-27.41%	50.71%	5.12%
Receivables	26.86	28.34	41.55	38.04	25.69
Inventory	6.46	7.88	9.03	8.46	7.11
Other Current Assets	15.89	43.99	18	17.46	13.46
Total Current Assets	540.13	508.02	545.74	721.32	482.43
Property, Plant & Equipment	0.99	3.28	6.33	5.2	10.41
Other Long-Term Assets	12.6	15.72	28.42	28.37	16.33
Total Long-Term Assets	13.58	19.01	34.75	33.57	26.74
Total Assets	553.71	527.02	580.49	754.89	509.17
Accounts Payable	116.98	103.78	171.04	153.97	105.11
Deferred Revenue	0	0	0	0	2.43
Current Debt	109.57	0	0	0	0
Other Current Liabilities	3.53	64.38	8.04	8.04	6.66
Total Current Liabilities	230.08	168.16	179.08	162.01	114.21
Long-Term Debt	223.1	539.78	560.58	532.08	371.25
Other Long-Term Liabilities	7.45	3.04	7.68	9.25	4.58
Total Long-Term Liabilities	230.56	542.82	568.27	541.33	375.83
Total Liabilities	460.63	710.99	747.34	703.33	490.04
Total Debt	332.67	539.78	560.58	532.08	371.25
Debt Growth	-38.37%	-3.71%	5.36%	43.32%	4.38%
Common Stock	2,238	2,309	2,234	2,176	1,800
Retained Earnings	-2,136.89	-2,489.77	-2,398.35	-2,123.47	-1,778.79
Comprehensive Income	-8.26	-2.87	-2.48	-1.14	-2.26
Shareholders' Equity	93.08	-183.96	-166.85	51.56	19.13
Net Cash / Debt	158.24	-111.97	-83.41	125.27	64.91
Net Cash / Debt Growth	-	-	-	92.99%	9.57%
Net Cash Per Share	4.68	-3.51	-2.53	3.96	2.28
Working Capital	310.05	339.86	366.67	559.31	368.22
Book Value Per Share	2.75	-5.77	-5.06	1.63	0.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).